v3.20.4

Transition Period - Unaudited Comparative Financial Information Statements of Operations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended										12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2018
Revenues
Total revenues	$ 148,222	$ 137,053	$ 121,297	$ 120,633	$ 109,076	$ 90,971	$ 72,038	$ 39,247	$ 6,654	$ 3,992	$ 527,205	$ 311,332	$ 12,737
Operating expenses
Cost of product sales									1,829	1,171	37,531	27,199	5,986
Research and development									29,086	36,195	205,396	142,678	153,736
Selling, general and administrative									49,083	25,174	336,043	259,880	141,818
Total operating expenses									79,998	62,540	578,970	429,757	301,540
Loss from operations	(22,812)	(12,721)	(9,039)	(7,193)	(20,108)	(17,658)	(29,322)	(51,337)	(73,344)	(58,548)	(51,765)	(118,425)	(288,803)
Interest income									2,449	604	1,814	8,464	3,645
Interest expense									(295)	(314)	(1,121)	(1,087)	(1,249)
Foreign exchange (loss) gain									(982)	160	(3,974)	(2,272)	(4,963)
Loss before income taxes									(72,172)	(58,098)	(55,046)	(9,203)	(291,370)
Income tax expense (benefit)									(266)	3,718	3,082	(184)	3,797
Net loss	$ (29,147)	$ (12,188)	$ (8,828)	$ (7,965)	$ (24,946)	$ (13,757)	$ 79,748	$ (50,064)	$ (71,906)	$ (61,816)	$ (58,128)	$ (9,019)	$ (295,167)
Net loss per common share, basic and diluted	$ (0.08)	$ (0.03)	$ (0.02)	$ (0.02)					$ (0.20)	$ (0.20)	$ (0.15)	$ (0.02)	$ (0.88)
Weighted average common shares outstanding, basic and diluted									366,458	313,730	375,586	371,580	333,936
Product Net Sales
Revenues
Total revenues									$ 6,617	$ 2,220	$ 526,830	$ 310,331	$ 10,469
Other Revenue
Revenues
Total revenues									$ 37	$ 1,772	$ 375	$ 1,001	$ 2,268

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

GW PHARMACEUTICALS PLC 10-K